Sort
50,496 grants matching “lung cancer”
BIODEGRADABLE NANOPARTICLE FORMULATED TAXOL FOR TARGETED THERAPY OF HEAD AND NECK
$441,856Shuming Nie · Emory University · P50 · FY2009 · CA
Molecular and cellular mechanisms of SCLC metastasis
$441,854Julien Sage · Stanford University · R01 · FY2017 · CA
Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer
$441,713Tamara Minko · Rutgers, The State Univ Of N.J. · R01 · FY2021 · CA
Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma
$441,695Markus Schober · New York University School Of Medicine · R01 · FY2022 · CA
A Role for KSHV in the Pathogenesis of Malignancies
$441,678Giovanna Tosato · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA
Targeting vulnerabilities in copper metabolism in the development of cancer therapies
$441,538Michael J Petris · University Of Missouri-Columbia · R01 · FY2024 · CA
Role of TbRIII in Regulating Motility and Invasion
$441,531Gerard C Blobe · Duke University · R01 · FY2010 · CA
TOTAL SYNTHESIS OF AZASPIRACIDS
$441,513Scripps Research Institute · R01 · FY2005 · ES
Regulation of tumor-infiltrating T cells by macrophages
$441,506Xiaopei Huang · Ohio State University · R01 · FY2025 · CA
Acid Ceramidase, Target for Cancer
$441,419Xiang Liu · Sphingogene, Inc. · R41 · FY2009 · CA
Implications of metabolic heterogeneity on collective lung cancer cell invasion
$441,390Malathy (mala) Shanmugam · Emory University · R01 · FY2022 · CA
Implications of metabolic heterogeneity on collective lung cancer cell invasion
$441,390Malathy (mala) Shanmugam · Emory University · R01 · FY2023 · CA
Integrated analyses of cancers harboring STK11 vs. TSC1/2 vs. PTEN Loss
$441,384David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2013 · CA
Developmental Funds
$441,375Caryn Lerman · University Of Southern California · P30 · FY2023 · CA
Implications of metabolic heterogeneity on collective lung cancer cell invasion
$441,333Malathy (mala) Shanmugam · Emory University · R01 · FY2025 · CA
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade
$441,312Craig Lewis Duvall · Vanderbilt University · R01 · FY2022 · CA
Role of DOCK8 in B Cell Function
$441,250Raif Salim Geha · Boston Children'S Hospital · R01 · FY2015 · AI
4'-Substituted nucleoside analogs as anticancer drugs
$441,240John A Secrist · Southern Research Institute · R01 · FY2012 · CA
4'-Substituted nucleoside analogs as anticancer drugs
$441,240John A Secrist · Southern Research Institute · R01 · FY2011 · CA
Development of caveolae-targeted antibody-drug conjugates
$441,222Bogdan Olenyuk · Proteogenomics Research Instit/Sys/ Med · P01 · FY2020 · CA
Discovery and therapeutic targeting of biological determinants of lung cancer health disparities
$441,169Sharon R. Pine · University Of Colorado Denver · R01 · FY2024 · CA
Regulation of tumor-infiltrating T cells by macrophages
$441,166Yiping Yang · Ohio State University · R01 · FY2021 · CA
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer
$441,162Qiang Shen · Lsu Health Sciences Center · R01 · FY2022 · CA
Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors
$441,155Grace E Dean · State University Of New York At Buffalo · R01 · FY2021 · NR
Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors
$441,155Grace E Dean · State University Of New York At Buffalo · R01 · FY2020 · NR